These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28524619)

  • 1. Use of complementary and alternative medicines is associated with delay to initiation of disease-modifying anti-rheumatic drug therapy in early inflammatory arthritis.
    Lahiri M; Santosa A; Teoh LK; Clayton JA; Lim SY; Teng GG; Cheung PPM
    Int J Rheum Dis; 2017 May; 20(5):567-575. PubMed ID: 28524619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking, but not use of complementary and alternative medicine predicts residual functional disability in patients with inflammatory arthritis on biologic disease-modifying anti-rheumatic drugs: Results from the Singapore National Biologics Register.
    Seet D; Yeo SI; Aw MH; Dhanasekaran P; Mui-San Lim R; Koh LW; Lahiri M
    Int J Rheum Dis; 2023 Mar; 26(3):510-518. PubMed ID: 36737417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database.
    Ranganath VK; Paulus HE; Onofrei A; Khanna D; Reed G; Elashoff DA; Kremer JM; Furst DE
    J Rheumatol; 2008 Oct; 35(10):1966-71. PubMed ID: 18785317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
    Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary and alternative medicine use in patients with chronic diseases in primary care is associated with perceived quality of care and cultural beliefs.
    Lee GB; Charn TC; Chew ZH; Ng TP
    Fam Pract; 2004 Dec; 21(6):654-60. PubMed ID: 15531625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: prognostic factors after two years of follow-up.
    Graell E; Vazquez I; Larrosa M; Rodríguez-Cros JR; Hernández MV; Gratacós J; Gómez A; Cañete JD; Gómez-Puerta JA; Sanmartí R
    Clin Exp Rheumatol; 2009; 27(2):284-91. PubMed ID: 19473570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.
    Contreras-Yáñez I; Pascual-Ramos V
    Arthritis Res Ther; 2015 Jul; 17(1):177. PubMed ID: 26162892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
    Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
    Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.
    Mjaavatten MD; Radner H; Yoshida K; Shadick NA; Frits ML; Iannaccone CK; Kvien TK; Weinblatt ME; Solomon DH
    Semin Arthritis Rheum; 2015 Feb; 44(4):399-404. PubMed ID: 25257807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and predictors of joint damage as assessed by the rheumatoid arthritis articular damage (RAAD) score in South Africans with established rheumatoid arthritis.
    Ickinger C; Musenge E; Tikly M
    Clin Rheumatol; 2013 Dec; 32(12):1711-7. PubMed ID: 24005837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis.
    Weng HH; Ranganath VK; Khanna D; Oh M; Furst DE; Park GS; Elashoff DA; Sharp JT; Gold RH; Peter JB; Paulus HE;
    J Rheumatol; 2010 Mar; 37(3):550-7. PubMed ID: 20110517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of adherence to disease modifying anti-rheumatic drugs in White British and South Asian patients with rheumatoid arthritis: a cross sectional study.
    Kumar K; Raza K; Nightingale P; Horne R; Chapman S; Greenfield S; Gill P
    BMC Musculoskelet Disord; 2015 Dec; 16():396. PubMed ID: 26714853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complementary and alternative medicine use in African Americans with rheumatoid arthritis.
    Tamhane A; McGwin G; Redden DT; Hughes LB; Brown EE; Westfall AO; Conn DL; Jonas BL; Smith EA; Brasington RD; Moreland LW; Bridges SL; Callahan LF
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):180-9. PubMed ID: 23983105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of early treatment on physical function in daily management of rheumatoid arthritis: a 5-year longitudinal study of rheumatoid arthritis patients in the National Database of Rheumatic Diseases in Japan.
    Hirata A; Suenaga Y; Miyamura T; Matsui T; Tohma S; Suematsu E; Ohnaka K; Takayanagi R
    Int J Rheum Dis; 2018 Apr; 21(4):828-835. PubMed ID: 27126059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
    Ajeganova S; van Steenbergen HW; van Nies JA; Burgers LE; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2016 May; 75(5):867-73. PubMed ID: 25972519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis.
    Molina E; Del Rincon I; Restrepo JF; Battafarano DF; Escalante A
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):940-6. PubMed ID: 25581770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.